


LABORATORY ALLIANCE of Central New York, LLC

Urine Drug Screens for Oxycodone and Buprenorphine

Laboratory Alliance is pleased to announce that screening assays for oxycodone and buprenorphine in urine will be added to our in-house urine toxicology menu effective June 30, 2015. Each of these assays will be available in two configurations: screening assay only, or screening with reflex to quantitative confirmatory assay if positive. Please note that these assays are separate requests from our urine drugs of abuse assays.

Oxycodone is a synthetic opioid compound which is commonly prescribed for pain management and has become a frequently abused drug. Although structurally very similar to naturally occurring opiates, oxycodone and its metabolites are not sufficiently detected by our automated opiate drug screen to trip a positive result except when very high levels are present. Therefore, the separate oxycodone screen (which also may detect the metabolite oxymorphone) will complement our existing menu, providing better coverage of the opiate and opioid narcotic drug classes.

Buprenorphine is used to treat dependence/addiction to narcotics (opioids). Buprenorphine alone (e.g. Subutex[®]) and the combination of buprenorphine and naloxone (e.g. Suboxone[®]) prevent withdrawal symptoms when someone stops taking opioid drugs by producing similar effects to these drugs. Buprenorphine belongs to a class of drugs called mixed narcotic agonist-antagonists. It is prescribed as part of a complete treatment program for drug abuse (such as compliance monitoring, counseling, behavioral contract, lifestyle changes), but like oxycodone, may also be abused. Buprenorphine is not currently detected by any of the assays in our existing in-house menu.

	Oxycodone	Buprenorphine
Test Name*:	OXYCODONE SCREEN UR	BUPRENORPH SCREEN UR
Test Code:	UOXY	UBUP
Cutoff:	100 ng/mL	10 ng/mL
Test Description:	Rapid, qualitative immunochromatographic assay. Reported as positive or negative. No additional testing is performed; quantitative confirmatory testing can be added if requested within 72 hours.	
Best used for:	Screening patient for non-prescribed drug use.	

	Oxycodone	Buprenorphine
Test Name*:	OXYCODONE W RFLX,UR	BUPRENORPH W RFLX,UR
Test Code:	UOXYWC	UBUPWC
Cutoff:	100 ng/mL	10 ng/mL
Test Description:	Rapid, qualitative immunochromatographic assay. Reported as positive or negative. If positive, additional testing is performed that will characterize and quantitate individual drugs and metabolites detected.	
Confirmatory Testing*:	OPIATES CFMR URINE (Oxycodone cutoff: 20 ng/mL) Detects and quantitates parent drug oxycodone and metabolite oxymorphone, as well as natural opiates and metabolites such as codeine, heroin metabolite (6-AM), hydrocodone and morphine.	BUPRENORPHINE&MET UR (Buprenorphine cutoff: 2 ng/mL) Detects and quantitates parent drug buprenorphine and metabolite norbuprenorphine, their glucuronide derivatives and related compound naloxone.
Best used for:	Screening and quantitating prescribed drugs. Please Note: For suspected non-compliance, a direct order for the quantitative assay may be preferred due to lower cutoff levels for positive results.	
Specimen Requirements:	Urine, 1 mL (min. 0.5 mL) 0.5 mL required for screen only	Urine, 3 mL (min. 1.5 mL) 0.5 mL required for screen only
Stability:	Ambient: 24 hours Refrigerated: 7 days	Ambient: 24 hours Refrigerated: 7 days
Testing Schedule:	Daily	Daily
CPT Codes:	80301	80301
Billing Codes:	1010500 (screen only) 1010501 (screen with reflex)	1010498 (screen only) 1010499 (screen with reflex)

* Test names are printed as they appear on the patient report

Questions regarding these tests may be directed to Cheryl Haskins, MS, MT(ASCP)SC, Manager, Chemistry and Referral Testing, at 315-410-7014 or cherylhaskins@lacny.com.

References:

1. PROFILE V Package Insert, MEDTOX Diagnostics Inc., Burlington, NC 27215
P/N 102038, Rev. 12/09

6/8/15, cmh